158 related articles for article (PubMed ID: 6342758)
21. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
22. Mouse monoclonal antibody to a melanoma-carcinoma-associated antigen synthesized by a human melanoma cell line propagated in serum-free medium.
Chee DO; Yonemoto RH; Leong SP; Richards GF; Smith VR; Klotz JL; Goto RM; Gascon RL; Drushella MM
Cancer Res; 1982 Aug; 42(8):3142-7. PubMed ID: 7046918
[TBL] [Abstract][Full Text] [Related]
23. Local infiltration of T-lymphocyte subsets as a prognostic indicator in patients with nasopharyngeal carcinoma.
Hsu MM
Ear Nose Throat J; 1990 Aug; 69(8):543-7. PubMed ID: 2204526
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
25. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
26. In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferations.
Duncan LM; Bouffard D; Howard C; Mihm MC; Byers HR
Mod Pathol; 1996 Sep; 9(9):938-43. PubMed ID: 8878027
[TBL] [Abstract][Full Text] [Related]
27. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
Holt JB; Sangueza OP; Levine EA; Shen P; Bergman S; Geisinger KR; Creager AJ
Am J Clin Pathol; 2004 Jan; 121(1):58-63. PubMed ID: 14750241
[TBL] [Abstract][Full Text] [Related]
28. Nuclear expression of the antiapoptotic protein survivin in malignant melanoma.
Ding Y; Prieto VG; Zhang PS; Rosenthal S; Smith KJ; Skelton HG; Diwan AH
Cancer; 2006 Mar; 106(5):1123-9. PubMed ID: 16456815
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues.
Dippold WG; Dienes HP; Knuth A; Meyer zum Büschenfelde KH
Cancer Res; 1985 Aug; 45(8):3699-705. PubMed ID: 3893688
[TBL] [Abstract][Full Text] [Related]
30. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.
Friedman RJ; Rigel DS; Kopf AW; Lieblich L; Lew R; Harris MN; Roses DF; Gumport SL; Ragaz A; Waldo E; Levine J; Levenstein M; Koenig R; Bart RS; Trau H
Arch Dermatol; 1983 Jun; 119(6):455-62. PubMed ID: 6859885
[TBL] [Abstract][Full Text] [Related]
31. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi.
Paul E; Cochran AJ; Wen DR
J Cutan Pathol; 1988 Jun; 15(3):161-5. PubMed ID: 2456315
[TBL] [Abstract][Full Text] [Related]
33. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
34. Eruptive nevi of the palms and soles.
Woodhouse J; Maytin EV
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S96-S100. PubMed ID: 15858520
[TBL] [Abstract][Full Text] [Related]
35. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
36. Patterns of melastatin mRNA expression in melanocytic tumors.
Deeds J; Cronin F; Duncan LM
Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
[TBL] [Abstract][Full Text] [Related]
37. Expression of thyrotropin-releasing hormone by human melanoma and nevi.
Ellerhorst JA; Naderi AA; Johnson MK; Pelletier P; Prieto VG; Diwan AH; Johnson MM; Gunn DC; Yekell S; Grimm EA
Clin Cancer Res; 2004 Aug; 10(16):5531-6. PubMed ID: 15328193
[TBL] [Abstract][Full Text] [Related]
38. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi.
Touab M; Arumi-Uría M; Barranco C; Bassols A
Am J Clin Pathol; 2003 Apr; 119(4):587-93. PubMed ID: 12710131
[TBL] [Abstract][Full Text] [Related]
39. Displacement of dermal solar elastosis in malignant melanoma.
Horenstein MG; Norton CL; Evans TN
J Cutan Pathol; 2007 May; 34(5):376-80. PubMed ID: 17448191
[TBL] [Abstract][Full Text] [Related]
40. [Halo nevus. In situ study using monoclonal antibodies].
Vignale RA; Paciel J; Bruno J; Calandría L; de Anda G
Med Cutan Ibero Lat Am; 1986; 14(1):13-7. PubMed ID: 2942737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
